EUVIMEDEUVIMED entdecken
Fallbericht

Quantifying Residual Rivaroxaban Plasma Concentration after Antagonization with Andexanet Alfa: A Difficult Task in Routine Clinical Practice

Alexander Mair, Gilles Huber, Jan-Dirk Studt, Donat R Spahn, Alexander Kaserer

Hämostaseologie · 01.04.2026 · 46 (02) · 106-110

DOI: 10.1055/a-2266-8021 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Hämostaseologie, erschienen am 01.04.2026. Verfasst von Alexander Mair und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Anesthesiology, University Hospital Zurich, Zurich, Switzerland. Hauptthemen laut MEDLINE: Rivaroxaban, Factor Xa. Die Arbeit nennt 11 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We describe the case of a 38-year-old man with a history of chronic portal vein thrombosis who presented with abdominal pain after a transjugular intrahepatic portosystemic shunt procedure. Under anticoagulation therapy with rivaroxaban, he experienced active splenic bleeding, leading to hemodynamic instability. Emergency interventions, including andexanet alfa and nanoparticle administration, successfully stopped the bleeding. However, routine tests showed persistently high rivaroxaban levels despite reversal with andexanet alfa. This case report shows that next to standard anti-Xa activity assay, high-performance liquid chromatography is as well unreliable in this regard. In contrast, viscoelastic tests might better serve as indicators of the efficacy of the reversal. The availability of modified anti-Xa tests is urgently needed, to monitor the effects of andexanet alfa reversal.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RivaroxabanFactor XaHumansAdultMaleRecombinant ProteinsFactor Xa InhibitorsTreatment Outcome

Substanzen

RivaroxabanRecombinant ProteinsFactor XaFactor Xa InhibitorsPRT064445

Autor:innen und Institutionen

  • Institute of Anesthesiology, University Hospital Zurich, Zurich, Switzerland.
  • Faculty of Medicine, University of Zurich, Zurich, Switzerland.
  • Division of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland.

Zitieren

APA

Mair, A., Huber, G., Studt, J. D., Spahn, D. R., & Kaserer, A. (2026). Quantifying Residual Rivaroxaban Plasma Concentration after Antagonization with Andexanet Alfa: A Difficult Task in Routine Clinical Practice. Hämostaseologie, 46(02), 106-110. https://doi.org/10.1055/a-2266-8021

Vancouver

Mair A, Huber G, Studt JD, Spahn DR, Kaserer A. Quantifying Residual Rivaroxaban Plasma Concentration after Antagonization with Andexanet Alfa: A Difficult Task in Routine Clinical Practice. Hämostaseologie. 2026;46(02):106-110. doi:10.1055/a-2266-8021

BibTeX
@article{Mair2026,
  author = {Mair, Alexander and Huber, Gilles and Studt, Jan-Dirk and Spahn, Donat R and Kaserer, Alexander},
  title = {Quantifying Residual Rivaroxaban Plasma Concentration after Antagonization with Andexanet Alfa: A Difficult Task in Routine Clinical Practice},
  journal = {Hämostaseologie},
  year = {2026},
  volume = {46},
  number = {02},
  pages = {106--110},
  doi = {10.1055/a-2266-8021}
}
Kostenlos starten →